Lupin Strengthens European Respiratory Portfolio with Acquisition of Sanofi Brands

Lupin Limited (Lupin), a leading global pharmaceutical company, announced the successful acquisition of two established brands from Sanofi. The transaction, completed by Lupin’s European hub entity, Lupin Atlantis Holdings SA, encompasses AaraneTM in Germany and NalcromTM in Canada and the Netherlands, along with associated trademark rights.

This strategic move aligns perfectly with Lupin’s focus on expanding its global footprint in the speciality pharmaceuticals segment, where the company enjoys a strong reputation for high-quality and innovative products. The acquisition of AaraneTM and NalcromTM specifically bolsters Lupin’s Respiratory business in Germany, providing a valuable boost to their recently launched LuforbecTM franchise.

By integrating these well-recognized brands into its portfolio, Lupin gains a foothold in established markets and strengthens its position as a key player in the European respiratory space. This strategic acquisition signifies Lupin’s commitment to delivering a wider range of high-quality respiratory treatment options to patients worldwide.

“This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastro-intestinal care that broaden our portfolio of branded products. We are committed to providing our customers and patients with the best products and services in the market segments where we are present, improving the quality of life for millions of people around the world,” said Dr Fabrice Egros, President – Corporate Development, Lupin.

About NalcromTM

NalcromTM (sodium cromoglicate Oral) belongs to a group of medicines called anti-allergics. It is used to treat food allergies after adequate testing for sensitivity to specific allergens in conjunction with restricting the main allergens.

About AaraneTM

AaraneTM (sodium cromoglicate/reproterol hydrochloride pressurised inhalation) is a chromone complex indicated for the symptomatic acute treatment of sudden asthma attacks (e.g., allergic forms or those triggered by exertion, stress, or infections) and the targeted prevention of exercise-induced asthma or in cases of foreseeable allergen contact.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.